Advanced Wound Care Firm Acelity Grabbed for $6.7 Billion

3m Company (NYSE: MMM), the global conglomerate, announced in early May it purchased Acelity Inc. for $6.7 billion, or roughly 11.4x EBITDA.  The target is a medical device consortium comprised of Apax Partners, affiliates of Canada Pension Plan Investment Board and the Public Sector Pension Investment Board, is selling Acelity. Acelity develops advanced wound care products and […]

Xiidra, Dry Eye Treatment Drug, Acquired by Novartis

The global pharmaceutical giant Novartis (NYSE: NVS) bought the assets to Xiidra 5% solution from Takeda Pharmaceutical Company (NYSE: TAK). The announcement gives us the largest pharmaceutical deal of the year so far, with Novartis paying $3.4 billion upfront and $1.9 billion in potential milestones for the drug. In 2018, Xiidra generated revenue of $400 million. Xiidra is the first and only […]

Small World: The Week of International Pharma Deals

Last week, the list of pharmaceutical deals announced also could have served as a geography lesson. Not only was the volume of deals particularly high, accounting for nearly 28% of the week’s total, but it had a diverse list of countries. Beginning in the United States, New York City-based Royalty Pharma, which focuses entirely on acquiring royalty interests […]